Intellia Therapeutics (Nasdaq: NTLA) reported that on August 1, 2026, it granted inducement equity awards to eight new employees under its 2024 Inducement Plan, as amended. The awards consist of time-based restricted stock units covering an aggregate of 38,200 shares of common stock, with one-third of the RSUs vesting annually over three years, subject to continued service. According to Intellia, these grants were made outside its stockholder-approved equity incentive plans under the 2024 Inducement Plan adopted in June 2024 and were approved by the compensation committee as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The prior inducement-grant event 1067582 was followed by a -0.37% 24-hour reaction, providing a dire...
Analysis
The prior inducement-grant event 1067582 was followed by a -0.37% 24-hour reaction, providing a directly comparable platform reference. Current context also recorded Net Selling and high short positioning; subsequent filings remain the key watchpoints.
Key Figures
Award date:August 1, 2026New employees:8 employeesShares granted:38,200 shares+3 more
6 metrics
Award dateAugust 1, 2026Inducement grants
New employees8 employeesRecipients of inducement grants
"focused on revolutionizing medicine leveraging CRISPR gene editing"
CRISPR gene editing is a laboratory technique that uses a guided molecular “scissor” to change DNA at specific locations, allowing scientists to add, remove, or correct genetic code. For investors, it matters because it underpins a new class of therapies and biotech products with high upside if they work, but also carries long development timelines, regulatory uncertainty, and technical risks that can create large swings in company value.
restricted stock unitsfinancial
"time-based restricted stock units (“RSUs”) for an aggregate of 38,200 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
inducement grantsfinancial
"it awarded inducement grants to eight new employees"
Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 38,200 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024.These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact: Jason Fredette Vice President, Investor Relations and Corporate Communications Intellia Therapeutics, Inc. jason.fredette@intelliatx.com
What inducement grants did Intellia Therapeutics (NTLA) announce on August 7, 2026?
Intellia Therapeutics announced inducement grants of time-based RSUs covering an aggregate of 38,200 shares for eight new employees. According to Intellia, these awards were granted on August 1, 2026, under its 2024 Inducement Plan as material inducements to employment.
How many shares are included in Intellia Therapeutics’ August 2026 inducement RSU grants (NTLA)?
The inducement RSU grants cover a total of 38,200 shares of Intellia Therapeutics common stock. According to Intellia, these time-based RSUs were awarded to eight new employees under the 2024 Inducement Plan as amended, outside stockholder-approved equity plans.
What is the vesting schedule for Intellia Therapeutics’ August 2026 inducement RSUs?
The RSUs vest in three equal annual installments, with one-third vesting each year over three years. According to Intellia, vesting is contingent on each recipient’s continued service as an employee or other service provider through the applicable vesting dates.
Under which plan were Intellia Therapeutics’ August 2026 inducement grants made?
The inducement grants were made under Intellia’s 2024 Inducement Plan, as amended. According to Intellia, this plan was initially adopted by the board of directors in June 2024 and operates separately from its stockholder-approved equity incentive plans.
How do Intellia Therapeutics’ inducement grants comply with Nasdaq Listing Rule 5635(c)(4)?
The grants were approved by Intellia’s compensation committee as material inducements to employment, aligning with Nasdaq Listing Rule 5635(c)(4). According to Intellia, this rule allows equity awards outside stockholder-approved plans when used as significant incentives for new hires.
How many employees received inducement RSUs from Intellia Therapeutics in August 2026?
Eight new employees received the inducement RSU awards in August 2026. According to Intellia, all awards were granted on August 1, 2026, as part of the company’s efforts to attract talent, under its 2024 Inducement Plan, as amended.
